Bridion

(Sugammadex)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Sugammadex is used to quickly reverse the effects of certain anesthesia drugs after surgery, helping patients wake up faster and recover from muscle paralysis caused during the operation.[2] Bridion is currently approved and in use across 32 indications[4].[1]

Bridion is one of 647 small molecule programs targeting Delirium. It is currently in Approved.

Indications

188

Total Trials

Active Trials

646

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

DeliriumActive, not recruiting

BurnApproved

Allergic DiseaseApproved

Organophosphate PoisoningApproved

Post Operative Nausea and VomitingApproved

Prostate CancerApproved

Kidney DiseaseApproved

Morbid ObesityApproved

Post-Operative Sign or SymptomApproved

ObesityApproved

DeliriumPreclinical

Active, not recruiting

BurnApproved

Approved

Allergic DiseaseApproved

Approved

Organophosphate PoisoningApproved

Approved

Post Operative Nausea and VomitingApproved

Approved

Prostate CancerApproved

Approved

Kidney DiseaseApproved

Approved

Morbid ObesityApproved

Approved

Post-Operative Sign or SymptomApproved

Approved

ObesityApproved

Approved

Showing 10 of 30 indications

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Opdivo

22 3

Lupron

EEastern Cooperative Oncology Group

Phase 3

53 4

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 5

Alinamin

Roche

Phase 3

6 6

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

14 7

LHRH Agonist

Roche

Phase 3

10 8

Gnrh Agonist/antagonist

NNorthwestern University

Phase 3

2 9

Piflufolastat F 18

Novartis

Phase 3

1 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

PreclinicalRecruiting

Residual Neuromuscular Block

NCT07309393

Q4 2026

PreclinicalRecruiting

Major Depressive Disorder

NCT07534475

Recruiting

Pediatric Cardiac Surgery

NCT07798011

Q3 2027

Post-ApprovalRecruiting

Chronic Kidney Disease

NCT07203287

Q4 2027

Post-ApprovalNot yet recruiting

Sugammadex

NCT07477132

Phase 3Not yet recruiting

Neuromuscular Blocking Agents

NCT07271875

Clinical

Trials by Indication[1]

Sugammadex26 trials

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

Completed·CClayton Petro·Phase 4·NCT05985343·184 enrolled

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00552929·102 enrolled

Investigation of Sugammadex in Outpatient Urological Procedures

Completed·MM.D. Anderson Cancer Center·Phase 4·NCT03138967·54 enrolled

Show 23 more trials

Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00751179·161 enrolled

Sugammadex and Brain Waves

Completed·TTampere University Hospital·Phase 4·NCT01142648·30 enrolled

A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00591409·100 enrolled

A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old

Not yet recruiting·UUniversity Hospital, Caen·Phase 4·NCT07477132·99 enrolled

Sugammadex To IMprove Bowel Function

Completed·OOregon Health and Science University·Phase 4·NCT04546672·120 enrolled

Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00702715·69 enrolled

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03519854·99 enrolled

Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00474253·115 enrolled

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00591786·100 enrolled

Placental Transfer of Sugammadex in the Human Placental Perfusion Model

Enrolling by invitation·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT06634355·16 enrolled

Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal

Completed·HHospital Sultanah Aminah Johor Bahru·Phase 4·NCT01539044·49 enrolled

Sugammadex as Rescue Therapy

Completed·EEmory University·Phase 4·NCT05661409·46 enrolled

Sugammadex and Decreased Time to Extubation

Completed·YYale University·Phase 4·NCT03196167·90 enrolled

Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery

Completed·TTechnical University of Munich·Phase 4·NCT01101139·300 enrolled

Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00535743·174 enrolled

A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00552617·100 enrolled

Improvement of Facial Nerve Monitoring in Parotid Surgery by Sugammadex

Completed·KKaohsiung Medical University Chung-Ho Memorial Hospital··NCT02314234·50 enrolled

Minimal Optimal Dose of Sugammadex in Elective Surgery

Completed·EErasme University Hospital·Phase 4·NCT03515694·40 enrolled

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00535496·91 enrolled

Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency

Completed·UUniversity of South Florida·Phase 4·NCT02860507·50 enrolled

Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00379613·45 enrolled

Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients

Completed·KKocaeli University·Phase 4·NCT01972659·80 enrolled

Sugammadex Dose Finding Under Two Years Old

Not yet recruiting·SSang-Hwan Ji·Phase 2·NCT06575036·33 enrolled

Neuromuscular Blockade25 trials

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

Completed·UUniversity of Kansas Medical Center·Phase 3·NCT03513406·7 enrolled

Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade

Unknown status·SSt. Antonius Hospital·Phase 3·NCT01855217·25 enrolled

Sugammadex Efficacy and Safety for Reversal of Pipecuronium-induced Neuromuscular Blockade

Unknown status·—·Phase 4·NCT01424488·42 enrolled

Show 22 more trials

Reversal of Neuromuscular Blockade in Thoracic Surgical Patients

Completed·EEndeavor Health··NCT01837498·200 enrolled

Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

Completed·—·Phase 4·NCT02708056·26 enrolled

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT03168308·92 enrolled

Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00758485·140 enrolled

The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

Completed·YYonsei University·N/A·NCT02109133·67 enrolled

Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00675792·100 enrolled

Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures

Completed·—·Phase 4·NCT02451202·102 enrolled

Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade

Completed·OOrdu University·Phase 4·NCT02215382·36 enrolled

Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

Completed·UUniversity of Missouri-Columbia·Phase 4·NCT03112993·40 enrolled

Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children

Completed·SSeoul National University Hospital·N/A·NCT05724550·73 enrolled

Effect of Neuromuscular Blockade and Reversal on Breathing

Completed·LLeiden University Medical Center·Phase 4·NCT02845375·46 enrolled

Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantation

Unknown status·GGuangzhou General Hospital of Guangzhou Military Command·Phase 4·NCT05187455·34 enrolled

Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade

Unknown status·GGuangzhou General Hospital of Guangzhou Military Command·Phase 4·NCT04131218·20 enrolled

Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients

Completed·MMatias Vested·Phase 4·NCT06228092·40 enrolled

"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"

Completed·—·Phase 4·NCT02375217·56 enrolled

Sugammadex Reversal of Neuromuscular Blockade and Postoperative Bleeding

Unknown status·MMansoura University·N/A·NCT02939430·40 enrolled

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

Unknown status·GGuangzhou General Hospital of Guangzhou Military Command·Phase 4·NCT05328778·48 enrolled

Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial

Completed·FFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia·Phase 3·NCT01809886·100 enrolled

Electromyographic Activity of the Respiratory Muscles During Neostigmine or Sugammadex Enhanced Recovery After Neuromuscular Blockade

Completed·OOnze Lieve Vrouw Hospital·Phase 4·NCT02403063·18 enrolled

Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients

Unknown status·UUniversity of Patras·Phase 2/3·NCT01629394·120 enrolled

Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Blockade

Unknown status·RRadboud University Medical Center·Phase 4·NCT01453530·30 enrolled

Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?

Completed·—·Phase 4·NCT02484651·70 enrolled

Neostigmine17 trials

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 4·NCT02410590

Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00825812·308 enrolled

Functional Respiratory Imaging After Neostigmine or Sugammadex

Completed·OOnze Lieve Vrouw Hospital·Phase 4·NCT02284412·13 enrolled

Show 14 more trials

Comparison of Time to Extubation Using Sugammadex or Neostigmine

Completed·TTemple University·Phase 4·NCT04606901·58 enrolled

Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium: Comparison Between Sugammadex Versus Neostigmine

Unknown status·MMansoura University·N/A·NCT02944175·40 enrolled

Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy

Terminated·EEmory University·Phase 4·NCT05256901·22 enrolled

Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00451100·84 enrolled

Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00473694·182 enrolled

Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00451217·198 enrolled

Comparison of the Impacts of Sugammadex With Neostigmine on Patency of Laryngeal Opening (Glottic Aperture Angle)

Unknown status·YYonsei University·N/A·NCT04545099·84 enrolled

A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia

Terminated·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 4·NCT02256280·70 enrolled

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01050543·128 enrolled

Neostigmine Versus Sugammadex on Renal Functions

Unknown status·MMenoufia University·Phase 4·NCT06081738·64 enrolled

Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine.

Completed·—·Phase 1·NCT06982092·60 enrolled

Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

Terminated·NNorthern Sydney Anaesthesia Research Institute·Phase 4·NCT02825576·30 enrolled

Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

Unknown status·IIuliu Hatieganu University of Medicine and Pharmacy·Phase 1·NCT03328312·90 enrolled

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

Completed·TThe Cleveland Clinic·Phase 4·NCT03322657·69 enrolled

Neuromuscular Block8 trials

The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients

Completed·SSeverance Hospital·N/A·NCT01890057·44 enrolled

The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block

Unknown status·—··NCT05841316·40 enrolled

The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT02580188·70 enrolled

Show 5 more trials

Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy

Unknown status·GGuangzhou General Hospital of Guangzhou Military Command·Phase 4·NCT05202899·40 enrolled

Sugammadex and Smoker's Neuromuscular Block

Completed·—·Phase 4·NCT05313100·40 enrolled

Deep Neuromuscular Block During General Anaesthesia in Robotic Surgery

Completed·UUniversity Hospital Olomouc·Phase 4·NCT03420937·138 enrolled

Deep vs Moderate Neuromuscular Blocks on Remifentanil for Laparoscopic Gastrectomy

Completed·—·N/A·NCT04205097·120 enrolled

Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography

Unknown status·UUniversity of Florence·Phase 4·NCT02698969·58 enrolled

Residual Neuromuscular Block7 trials

Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex

Unknown status·SSeoul National University Hospital··NCT05760560·52 enrolled

Sugammadex and Neostigmine at Residual Neuromuscular Blockade

Completed·TTechnical University of Munich··NCT01006720·99 enrolled

Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine

Completed·GGuangzhou General Hospital of Guangzhou Military Command··NCT03656614·121 enrolled

Show 4 more trials

Residual Neuromuscular Blockade in Cardiac Surgery Patients

Withdrawn·HHenry Ford Health System·Phase 4·NCT03574337

Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery

Completed·SSeoul National University Bundang Hospital·N/A·NCT03292965·80 enrolled

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

Completed·MMayo Clinic·Phase 4·NCT02728726·260 enrolled

Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function After Thoracoscopic Lung Resection: A Multicenter, Randomized, Double-Blind, Controlled Trial

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Preclinical·NCT07309393·240 enrolled

75 more indications

Urinary retention5 trials

The Role of Sugammadex in Posotoperative Urinary Retention in Patients Undergoing Pelvic Floor Reconstructive Procedures

Withdrawn·WWest Virginia University·Phase 1/2·NCT05664633

Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block

Completed·TThe Cleveland Clinic·Phase 4·NCT05545280·50 enrolled

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

Enrolling by invitation·UUniversity of Missouri-Columbia·Phase 4·NCT05887375·118 enrolled

Show 2 more trials

The POUR (Postoperative Urinary Retention) Study

Completed·WWake Forest University Health Sciences·Phase 3·NCT05276804·171 enrolled

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT05794503·235 enrolled

Neuromuscular Blocking Agents3 trials

Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals

Completed·JJakob Louis Thomsen··NCT02914119·30,430 enrolled

Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)

Completed· Merck & Co. logo

Merck & Co.··NCT01213264·659 enrolled

Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery

Not yet recruiting·XXijing Hospital·Phase 3·NCT07271875·560 enrolled

Effectiveness3 trials

A Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Sugammadex Versus Neostigmine in Improving Surgical Condition in Subjects Undergoing Laryngeal Microsurgery

Completed·YYonsei University·N/A·NCT01980069·72 enrolled

Effectiveness of Sugammadex in LMS Surgery

Unknown status·KKorea University Anam Hospital·Phase 4·NCT02329964·80 enrolled

Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex

Not yet recruiting·—·N/A·NCT05751603·66 enrolled

Laparoscopic Cholecystectomy3 trials

Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT04332627·77 enrolled

A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01728584·127 enrolled

Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00724932·140 enrolled

Paralysis3 trials

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

Completed·WWest Virginia University·Phase 4·NCT03111121·79 enrolled

Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine

Completed·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·Phase 4·NCT05066035·113 enrolled

Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·N/A·NCT01503840·20 enrolled

Efficacy and Safety3 trials

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2/3·NCT03728543·62 enrolled

Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries

Withdrawn·MMontefiore Medical Center·Phase 4·NCT03944473

Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00826176·164 enrolled

Sevoflurane3 trials

Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00559468·52 enrolled

Effect of Rocuronium and Sugammadex Under Sevoflurane and Desflurane Anesthesia in Children

Completed·IIstanbul University·N/A·NCT03795259·148 enrolled

Recovery After Sugammadex(Propofol vs Sevoflurane)

Completed·HHopital Foch·Phase 4·NCT01579851·71 enrolled

Anesthesia3 trials

Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00298831·224 enrolled

Recovery From Anesthesia After Robotic Assisted Radical Cystectomy

Unknown status·RRegina Elena Cancer Institute·Phase 4·NCT03144453·50 enrolled

Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01479764·154 enrolled

Muscle Relaxation2 trials

Muscle Relaxation for Pediatric Adenotonsillectomy

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT06225466·172 enrolled

Effect of Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Recording

Completed·—·N/A·NCT04608682·170 enrolled

Muscle Relaxant2 trials

Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates

Unknown status·—·N/A·NCT04566796·60 enrolled

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT03116997·201 enrolled

Obstructive Sleep Apnea2 trials

Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea

Completed·—·Phase 4·NCT02160223·74 enrolled

Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine

Completed·UUniversity of California, San Diego·Phase 4·NCT04570150·90 enrolled

Glycopyrrolate2 trials

Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

Completed·CCiusss de L'Est de l'Île de Montréal·Phase 4·NCT05718934·144 enrolled

Sugammadex v.s. Neostigmine/Glycopyrrolate

Completed·NNational Taiwan University Hospital·N/A·NCT06398899·124 enrolled

Nausea and vomiting2 trials

Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting.

Completed·OOrdu University·Phase 4·NCT02286752·98 enrolled

Sugammadex Versus Neostigmine for Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery

Completed·KKK Women's and Children's Hospital·Phase 3·NCT02666014·184 enrolled

Delirium2 trials

The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium

Unknown status·KKonkuk University Medical Center··NCT02305589·250 enrolled

Effect of Sugammadex vs. Neostigmine/Glycopyrrolate on Pediatric Emergence Delirium in Sevoflurane-rocuronium Anesthesia

Completed·PPusan National University Yangsan Hospital·Phase 4·NCT03229486·40 enrolled

Hip Fracture2 trials

Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01422304·1,198 enrolled

GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture

Withdrawn·LLoyola University·Phase 4·NCT03226080

Bariatric Surgery2 trials

Sugammadex on Laparoscopic Bariatric Surgery

Not yet recruiting·SShanxi Bethune Hospital·N/A·NCT06678451·60 enrolled

Deep Neuromuscular Relaxation Optimizing Low-Pressure Bariatric Surgery

Unknown status·MMcMaster University·N/A·NCT03803982·100 enrolled

Cognitive Function2 trials

Quality of Awakening and Impact on Cognitive Function After Administration of Sugammadex in Robotic Radical Cystectomy

Completed·RRegina Elena Cancer Institute·N/A·NCT02454504·120 enrolled

Sugammadex and Cognitive Function

Completed·—·N/A·NCT02419352·160 enrolled

Safety and Efficacy2 trials

Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00420680·120 enrolled

Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00475215·86 enrolled

Remifentanil2 trials

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female

Completed·—·N/A·NCT04407078·40 enrolled

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male

Completed·—·N/A·NCT03583021·42 enrolled

Cardiac Surgery2 trials

Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery

Unknown status·—·Phase 4·NCT03460509·144 enrolled

Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo

Active, not recruiting·EEndeavor Health·Phase 3·NCT05801679·175 enrolled

Abdominal Surgery1 trial

Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery

Completed·HHerlev Hospital·Phase 4·NCT02079337·14 enrolled

Ophthalmic Surgery1 trial

Sugammadex and Time to Extubation in Ophthalmic Surgery

Completed·—··NCT06632067·262 enrolled

Myasthenia Gravis1 trial

Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis

Completed·—·N/A·NCT06436768·62 enrolled

Arrhythmia1 trial

Reversal of Neuromuscular Blockade and Perioperative Arrhythmias

Completed·UUnknown Sponsor·N/A·NCT04720573·80 enrolled

Critically Ill1 trial

The Use of Sugammadex in the Critically Ill

Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT03791801·50 enrolled

Poisoning1 trial

A Pilot Study Using Rocuronium to Prevent Intermediate Syndrome After Organophosphorus Insecticide Poisoning

Completed·UUniversity of Edinburgh·Phase 2/3·NCT02147054·45 enrolled

Gynecologic Laparoscopic Surgery1 trial

Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade

Completed·HHerlev Hospital·Phase 4·NCT01933425·14 enrolled

Gastrectomy1 trial

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

Terminated·VVirtua Health, Inc.·Phase 4·NCT03276026·68 enrolled

Postoperative Recovery1 trial

Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile

Completed·LLeiden University Medical Center·Phase 4·NCT02243943·100 enrolled

Elderly Participants1 trial

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00474617·162 enrolled

Dexamethasone1 trial

Effect of Dexamethasone on the Action of Sugammadex

Completed·—·N/A·NCT02510157·44 enrolled

Heart Failure1 trial

Sugammadex and Heart Failure

Completed·OOnze Lieve Vrouw Hospital·Phase 3·NCT01509651·12 enrolled

Neuromuscular Blockade Reversal Agent1 trial

Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children

Completed·—·Phase 4·NCT02455921·200 enrolled

Hypothermia1 trial

Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex

Completed·MMSD Korea Ltd.·Phase 4·NCT01965067·60 enrolled

General Anesthesia1 trial

The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery

Completed·SSecond Affiliated Hospital of Guangzhou Medical University·N/A·NCT04944303·52 enrolled

Nausea1 trial

Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

Completed·SStony Brook University·Phase 4·NCT03435003·83 enrolled

Hysterectomy1 trial

Role of Curarization During Anesthesia for Laparoscopic Hysterectomy

Completed·—·Phase 2·NCT03519633·238 enrolled

Impaired Renal Function1 trial

Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00482599·30 enrolled

Major Abdominal Surgery1 trial

Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery

Completed·EEnrique Alday Muñoz·Phase 4·NCT02361060·130 enrolled

Complication1 trial

The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications

Completed·OOregon Health and Science University·Phase 4·NCT02861131·200 enrolled

Body Weight1 trial

The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.

Completed·—·N/A·NCT03381209·60 enrolled

Renal insufficiency1 trial

Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02011490·33 enrolled

Shoulder pain1 trial

Neuromuscular Blockade on Shoulder Pain of Elderly

Completed·MM.D. Anderson Cancer Center·Phase 4·NCT03210376·100 enrolled

Laparotomy1 trial

Role of Curarization During Anesthesia for Gynecologic Surgical Laparotomy Procedures

Unknown status·—·Phase 2·NCT03519724·100 enrolled

Laparoscopic1 trial

Atropine in Laparoscopic Gynaecological Surgery

Unknown status·CClinica Santa Maria·Phase 4·NCT02769325·150 enrolled

Intraoperative1 trial

Effect of Sugammadex for Muscle Motor Response and Awareness in Intraoperative Wakeup

Completed·—·Phase 4·NCT02390817·60 enrolled

Surgical1 trial

Effect of NMBA on Surgical Conditions in THR

Withdrawn·AAlgemeen Ziekenhuis Maria Middelares·Phase 4·NCT03369782

Cirrhosis1 trial

Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection

Completed·—·Phase 4·NCT02414880·60 enrolled

Colorectal Cancer1 trial

The Effect of Sugammadex on the Outcome After Colorectal Cancer Surgery

Completed·—··NCT03619759·585 enrolled

Critically Ill Patients1 trial

Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients

Recruiting·SSeoul National University Hospital·N/A·NCT05993390·30 enrolled

Completed·UUniversity of Melbourne·Phase 4·NCT03034577·350 enrolled

Dialysis Patients1 trial

A Pharmacokinetic Study of Sugammadex in Dialysis Patients

Withdrawn·TTetsuro Sakai·Phase 1·NCT04556721

Enhanced Recovery After Surgery1 trial

Enhanced Recovery After Surgery for Anterior Cervcial Spine Surgeries in Elderly Patients

Unknown status·TTaipei Veterans General Hospital, Taiwan·N/A·NCT04161508·100 enrolled

Pediatric Patients1 trial

PKPD of Rocuronium and Sugammadex Profile in Pediatric Patients

Completed·PPoznan University of Medical Sciences··NCT04851574·37 enrolled

Pediatric1 trial

Different Reversal Agents in Pediatric Day-case Cancer Surgery

Unknown status·NNational Cancer Institute, Egypt·Phase 4·NCT03996655·80 enrolled

Adverse Events1 trial

Perioperative Respiratory Adverse events_sugammadex

Completed·SSeoul National University Hospital·Phase 4·NCT05354466·174 enrolled

Randomized1 trial

A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo

Completed·UUniversity Health Network, Toronto·Phase 4·NCT03087513·40 enrolled

Observational Study1 trial

An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd··NCT05788718·6,458 enrolled

Kidney Transplant1 trial

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

Completed·UUniversity of Colorado, Denver·Phase 4·NCT03923556·84 enrolled

Bladder Cancer1 trial

Neuromuscular Blockade During Transurethral Resection of Bladder Cancer

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT03039543·108 enrolled

Quality of Recovery1 trial

Quality of Recovery After Reversal With Neostigmine or Sugammadex.

Completed·SStony Brook University·Phase 4·NCT02909439·80 enrolled

Chronic Kidney Disease1 trial

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

Recruiting·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT07203287·490 enrolled

Postoperative Quality of Recovery1 trial

Comparison the Postoperative Quality of Recovery Between Neostigmine and Sugammadex in Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia -Randomized Controlled Trial-

Completed·YYonsei University·N/A·NCT03108989·90 enrolled

Coronary Artery Bypass1 trial

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

Completed·WWest Virginia University·Phase 4·NCT03939923·84 enrolled

Laparoscopic Abdominal Surgery1 trial

Effects of Sugammadex and Conventional Reversal on Lung Function in Laparoscopic Abdominal Surgery

Unknown status·RRhendra Hardy Mohamad Zaini·N/A·NCT06210165·80 enrolled

Hemodynamic1 trial

Sugammadex: Effect on the Awareness Monitoring and Hemodynamics

Unknown status·UUniversity of Athens·N/A·NCT01301261·60 enrolled

Spinal Surgery1 trial

The Effect of Sugammadex During Transcranial Electrical Motor Evoked Potential Monitoring in Spinal Surgery

Completed·—·N/A·NCT04471376·66 enrolled

Renal Impairment1 trial

Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00656799·6 enrolled

Recurrent Laryngeal Nerve1 trial

The Improvement of Intraoperative Neuromonitoring of Recurrent Laryngeal Nerve

Completed·KKaohsiung Medical University Chung-Ho Memorial Hospital·N/A·NCT03911232·60 enrolled

Hypersensitivity1 trial

A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02028065·382 enrolled

Pediatric Cardiac Surgery1 trial

Precision Neuromuscular Management: Quantitative TOF-Guided Sugammadex Versus Spontaneous Recovery for Early Extubation in Pediatric Minimally Invasive Cardiac Surgery (A Prospective Observational Cohort Study)

Recruiting·DDr. Nguyen Thi Thu Hang··NCT07798011·80 enrolled

Intestinal Disease1 trial

Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation For Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial For Quality Improvement

Completed·UUniversity of California, Irvine·Approved·NCT06112353·132 enrolled

Major Depressive Disorder1 trial

Comparison of Venous Tourniquet Method With Isolated Forearm Technique in Electroconvulsive Therapy in Terms of Efficacy and Safety

Recruiting·MMedipol University·Preclinical·NCT07534475·20 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 15, 2015

BRIDION

NDA NDA022225

Sources

References

[1]
ClinicalTrials.gov — 188 trial records for Sugammadex. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Bridion drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Sugammadex compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Sugammadex. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022225). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Bridion. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Patent Landscape[6]

Patent #Expires

RE44733Jan 27, 2026

RE44733*PEDJul 27, 2026

Bridion

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2027

Q4 2027

Trials by Indication[1]

Sugammadex26 trials

Neuromuscular Blockade25 trials

Neostigmine17 trials

Neuromuscular Block8 trials

Residual Neuromuscular Block7 trials

Urinary retention5 trials

Neuromuscular Blocking Agents3 trials

Effectiveness3 trials

Laparoscopic Cholecystectomy3 trials

Paralysis3 trials

Efficacy and Safety3 trials

Sevoflurane3 trials

Anesthesia3 trials

Muscle Relaxation2 trials

Muscle Relaxant2 trials

Obstructive Sleep Apnea2 trials

Glycopyrrolate2 trials

Nausea and vomiting2 trials

Delirium2 trials

Hip Fracture2 trials

Bariatric Surgery2 trials

Cognitive Function2 trials

Safety and Efficacy2 trials

Remifentanil2 trials

Cardiac Surgery2 trials

Abdominal Surgery1 trial

Ophthalmic Surgery1 trial

Myasthenia Gravis1 trial

Arrhythmia1 trial

Critically Ill1 trial

Poisoning1 trial

Gynecologic Laparoscopic Surgery1 trial

Gastrectomy1 trial

Postoperative Recovery1 trial

Elderly Participants1 trial

Dexamethasone1 trial

Heart Failure1 trial

Neuromuscular Blockade Reversal Agent1 trial

Hypothermia1 trial

General Anesthesia1 trial

Nausea1 trial

Hysterectomy1 trial

Impaired Renal Function1 trial

Major Abdominal Surgery1 trial

Complication1 trial

Body Weight1 trial

Renal insufficiency1 trial

Shoulder pain1 trial

Laparotomy1 trial

Laparoscopic1 trial

Intraoperative1 trial

Surgical1 trial

Cirrhosis1 trial

Colorectal Cancer1 trial

Critically Ill Patients1 trial

Liver Transplant1 trial

Diaphragm Ultrasound1 trial

Laparoscopic Surgery1 trial

Dialysis Patients1 trial

Enhanced Recovery After Surgery1 trial

Pediatric Patients1 trial

Pediatric1 trial

Adverse Events1 trial

Randomized1 trial

Observational Study1 trial

Kidney Transplant1 trial

Bladder Cancer1 trial

Quality of Recovery1 trial

Chronic Kidney Disease1 trial

Postoperative Quality of Recovery1 trial

Coronary Artery Bypass1 trial